Insmed (INSM) Common Equity (2010 - 2026)

Insmed's Common Equity history runs 17 years deep, the most recent figure standing at $704.9 million for Q1 2026.

• On a quarterly basis, Common Equity rose 610.83% year-over-year to $704.9 million in Q1 2026; TTM through Mar 2026 was $704.9 million, a 610.83% increase from a year earlier, with the FY2025 full-year figure at $739.0 million, up 158.95% from the prior year.
• Common Equity fell to $704.9 million in Q1 2026 per INSM's latest filing, from $739.0 million in the prior quarter.
• Across five years, Common Equity topped out at $1.2 billion in Q2 2025 and bottomed at -$464.8 million in Q1 2024.
• The 5-year median for Common Equity is $88.0 million (2022), against an average of $204.8 million.
• Across the five-year window, Common Equity plunged 940.93% in 2024 and surged 3119.47% in 2025, its largest moves.
• Year by year, Common Equity stood at $88.0 million in 2022, then tumbled by 477.4% to -$331.9 million in 2023, then surged by 185.98% to $285.4 million in 2024, then surged by 158.95% to $739.0 million in 2025, then fell by 4.62% to $704.9 million in 2026.
• Per Business Quant, the three latest INSM Common Equity figures stand at $704.9 million (Q1 2026), $739.0 million (Q4 2025), and $945.6 million (Q3 2025).